Signatera™ is a highly sensitive and personalized MRD assay using ctDNA and is custom designed for each patient to help identify relapse earlier than standard of care tools

Signatera is a new blood test that can identify molecular residual disease (MRD), or recurrent cancer, sooner than existing methods by detecting the presence of circulating tumor DNA …

Nov 30, 2023 · "The Signatera™ Residual Disease Test is a custom-built blood test for people who have been diagnosed with breast cancer or other solid tumors. Signatera™ can detect …

Nov 7, 2025 · The Signatera™ test looks for the DNA of YOUR cancer in your blood to detect residual or recurrent cancer. They do this by making a lab assay using the tissue specimen …

Jul 23, 2025 · Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously …

Signatera (Natera) is a personalised molecular residual disease (MRD) assay that measures circulating tumour DNA (ctDNA) in the body.

Signatera assay is an individualised, tumor-informed test that detects residual disease using circulating tumor DNA (ctDNA) in the blood of patients previously diagnosed with cancer.

Test Information: Signatera™ is a mPCR-NGS assay for detection and quantification of circulating tumor DNA (ctDNA) in the plasma of patients previously diagnosed with cancer. Individual …

Visit the appropriate Natera ™ portal to check on results, schedule conversations with genetic counselors, place orders, or make payments. Check on your test status, view and download …

Signatera is a custom-designed test generated based on each patient’s unique set of tumor mutations. Knowing earlier if your cancer is likely to recur or has progressed after treatment …